Robert W. Baird Reaffirms Their Buy Rating on Zimmer Biomet Holdings (ZBH)

Robert W. Baird analyst Jeff Johnson reiterated a Buy rating on Zimmer Biomet Holdings (ZBHResearch Report) on November 2 and set a price target of $138.00. The company’s shares closed yesterday at $105.42.

According to TipRanks, Johnson is a 5-star analyst with an average return of 17.1% and a 53.44% success rate. Johnson covers the Healthcare sector, focusing on stocks such as DENTSPLY SIRONA, Align Tech, and Cooper Co.

Zimmer Biomet Holdings has an analyst consensus of Hold, with a price target consensus of $121.22, which is a 14.99% upside from current levels. In a report released yesterday, JMP Securities also maintained a Buy rating on the stock with a $145.00 price target.

See the top stocks recommended by analysts >>

ZBH market cap is currently $22.6B and has a P/E ratio of 81.81.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Zimmer Biomet Holdings, Inc. is a musculoskeletal healthcare company. The company engages in designing, manufacturing and marketing orthopedic reconstructive products; biologics, sports medicine, extremities and trauma products; spine, dental implants, bone healing, craniomaxillofacial and thoracic products; and related surgical products.

Read More on ZBH:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed